BBIO (NASDAQ: BBIO) trust sells repeated 20,000-share blocks under 10b5-1
A Form 144 filing indicates that trusts associated with Kumar Haldea have been consistently selling 20,000-share blocks of BridgeBio Pharma (NASDAQ: BBIO) common stock under 10b5-1 plans. These transactions, reported through Morgan Stanley Smith Barney LLC, occurred on various dates in March, April, and May 2026, with significant aggregate dollar proceeds per sale. The filing also notes a restricted stock unit entry, although it specifies this is a notice of proposed sale rather than a confirmation of holdings or settlement amounts.
MAY 15·AD HOC NEWS▲
BridgeBio Pharma stock (US10806X1028): Pipeline progress in rare diseases
BridgeBio Pharma is advancing its pipeline focusing on rare genetic disorders and cancers, including significant progress in its TTR amyloidosis program. The company leverages a platform approach through subsidiaries and has over 30 programs in clinical and preclinical stages, with revenue driven by pipeline milestones and partnerships. Investors are closely watching upcoming data readouts and collaborations, positioning BridgeBio as a key player in precision biotech for high-growth rare disease therapies.
MAY 14·TipRanks▲
BridgeBio Files FDA NDA for Encaleret in ADH1
BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for encaleret to treat autosomal dominant hypocalcemia type 1 (ADH1) following successful Phase 3 trial results. The drug demonstrated rapid and sustained normalization of calcium metabolism in patients and a favorable safety profile. With a "Buy" rating from analysts and a $101.00 price target, encaleret is poised to be the first approved therapy for ADH1, with potential for expansion into pediatric ADH1 and chronic hypoparathyroidism.
